"10.1371_journal.pone.0038364","plos one","2012-06-15T00:00:00Z","Cornelia Schuster; Hans P Eikesdal; Hanne Puntervoll; Jürgen Geisler; Stephanie Geisler; Daniel Heinrich; Anders Molven; Per E Lønning; Lars A Akslen; Oddbjørn Straume","Department of Oncology, Haukeland University Hospital, Bergen, Norway; Section for Pathology, The Gade Institute, University of Bergen, Bergen, Norway; Department of Pathology, Haukeland University Hospital, Bergen, Norway; Division of Clinical Medicine and Laboratory Sciences, Institute of Clinical Medicine, University of Oslo, Oslo, Norway; Department of Oncology, Akershus University Hospital, Lørenskog, Norway","Conceived and designed the experiments: OS LA PL. Performed the experiments: CS HE HP JG SG DH OS. Analyzed the data: CS HE HP AM PL LA OS. Contributed reagents/materials/analysis tools: HP AM. Wrote the paper: CS HE HP JG SG DH AM PL LA OS.","As stated above, the project has received funding from a commercial source (Roche Norway). This includes support for running costs as well as a price reduction for the investigational drug. This study involves Bevacizumab, which is a Roche product. This does not alter the authors adherence to all the PLoS ONE policies on sharing data and materials.","2012","06","Cornelia Schuster","CS",10,TRUE,3,7,7,10,TRUE,TRUE,FALSE,0,NA,FALSE
